Certainty at a time of uncertainty: An accurate picture of circulating SARS-CoV-2 variants
Mutants, variants and vaccines: The twists and turns in the continually evolving COVID-19 pandemic
Since its emergence globally in early 2020, SARS-CoV-2 has continued to evolve and accumulate new mutations, some of which have conferred phenotypic advantages. The need for increased viral sequencing has exploded ever since the Alpha variant, otherwise known as B1.1.7, was first detected. The Alpha, Beta, Gamma, Delta, Mu and Omicron variants have presented with spike protein mutations that in some cases increase the transmissibility of the virus. The rise of these “Variants of Concern” (VOC)* and “Variants of Interest” (VOI)* has triggered a requirement for fast, accurate and scalable viral sequencing to match global demand.
Innovation at the heart of the public health response
From the start, public health labs were challenged with sequencing increasing numbers of samples and a growing need to ramp up genomic surveillance efforts. Determining the prevalence of circulating variants within the population was critical to enable the timely implementation of effective public health measures. With cases rising worldwide, highly transmissible, emerging variants were changing the trajectory of the pandemic. Faster, more accurate and high-throughput technologies were necessary to accelerate SARS-CoV-2 genomic surveillance efforts.
The hunt for potential new ‘vaccine escape’ mutants
Early reports of reinfection with SARS-CoV-2 meant greater scrutiny into circulating variants was necessary to determine whether specific mutations could enable the virus to evade the immune response (1). This meant a deeper look at variants responsible for ‘breakthrough infections.’ The hunt was on to track and trace potential new ‘vaccine escape’ mutants.
While technologies such as PCR are efficient at detecting existing variants, whole genome sequencing provides an unprecedented level of insight into the viral genome – and helps pinpoint new mutations as they arise. With the development of the QIAseq SARS-CoV-2 Primer Panel in June 2020, QIAGEN provided an optimized ARTIC-based NGS solution for targeted enrichment of the complete viral genome. Compared with other SARS-CoV-2 whole genome sequencing methods, the QIAseq SARS-CoV-2 Primer Panel enables preferential amplification of the SARS-CoV-2 genome by up to 100-fold and ensures high coverage, as shown in a published technology comparison study by Liu et al. (2).
COVID-19 in animals
There have been reports of cats, dogs and even zoo animals testing positive for – and indeed dying of – COVID-19. In June 2020, Danish mink farmers noticed that their animals were showing signs of respiratory illness. It was confirmed that mink had been infected with SARS-CoV-2 from humans. The virus then leaped from the mink back to humans. As a consequence of this compelling observation, the Danish government decided to sequence every positive COVID-19 case in Denmark.
SARS-CoV-2 and wastewater testing
Wastewater-based epidemiology (WBE) is gaining momentum globally as a key approach to predicting and tracking the spread of COVID-19. NGS can provide additional insight in this field compared to PCR approaches as its possible to sequence the entire viral genome at depth with optimized workflows, from sample prep to data analysis. This means that NGS can be used to alert authorities of potentially new variants and strains in a population, even before these variants are detected in clinical cases (3).
Dr. Davida Smyth, Associate Professor of Microbiology at Texas A&M University San Antonio, Texas, and her collaborators have been tracking and monitoring SARS-CoV-2 from New York City wastewater samples (4). “If you are doing wastewater epidemiology for surveillance, you need to be able to compare across samples,” she stated. Every wastewater sample is different, with varying levels of RNA and inhibitors. “Each RNA sample that we get is different, and we only have a small volume of it. You’re getting a mixture of genetic material, and you're getting viruses and bacteria as well, you're getting the genomic signature from the hosts that have also contributed to the water“, she explained. With resources stretched and ongoing shortages with plasticware such as filter tips, processing large numbers of samples was increasingly becoming a challenge. The lab needed a fast, reliable NGS solution that reduced its dependency on plasticware. High genome coverage and uniformity were also critical parameters for variant-calling in wastewater samples.
The tiling amplicon design of the QIAseq DIRECT SARS-CoV-2 Kit generates high-yield libraries with superior sequence uniformity and depth of coverage. The accelerated workflow, increased throughput and reduced need for plasticware make the QIAseq DIRECT SARS-CoV-2 Kit highly suited for wastewater monitoring.
Davida and her team decided to complement their targeted sequencing approach for wastewater samples with whole genome sequencing using the QIAseq DIRECT SARS-CoV-2 Kit, as well as other similar solutions. “Whole genome sequencing gives us a snapshot of the entire genome. We want to see if there are additional locations across the [SARS-CoV-2] genome that are under selection or are behaving differently with respect to the vaccine interventions and so on. “Out of the whole genome sequencing kits we worked with, the coverage with the QIAseq DIRECT SARS-CoV-2 Kit was far better”, she emphasized.
Altered miRNA expression in COVID-19 patientsDetermining the host response to SARS-CoV-2 infection can provide invaluable insights into viral pathogenesis and COVID-19 progression. miRNAs are promising biomarkers of infectious disease. Their altered expression in COVID-19 patients can help predict SARS-CoV-2 infection with high accuracy. In a recent study, Dr. Ryan Farr and his team from the Australian Centre for Disease Preparedness (ACDP), CSIRO, investigated circulating miRNA profiles in the plasma of ten COVID-19 patients and ten age- and gender-matched healthy donors. Using the QIAseq miRNA Library Kit and QIAseq miRNA NGS 48 Index IL, they determined that among patient samples collected during early-stage disease, COVID-19 induced differential expression of 55 host-encoded miRNAs, with miR-31, -4742 and -3125 strongly up-regulated and miR-1275, -3617 and -500b down-regulated. The study revealed that three miRNAs (miR-423-5p, miR-23a-3p and miR-195-5p) could identify early-stage COVID-19 with 99.9% accuracy. This three-miRNA “plasma signature” returned to that of healthy controls as patients recovered from disease (5).
Pandemic preparedness and future outlooks
As one of the most influential global events in the last 100 years, it is an understatement to say that the COVID-19 pandemic has turned the world upside down. This public health emergency has had a devastating impact on many lives and economies and has plunged the world into a ‘new normal’ where we’ve had to adapt our lives dramatically. It has indisputably highlighted the need for pandemic preparedness moving forward. There is a clear requirement for robust, reliable technologies for the detection, testing and surveillance of infectious agents to enable an effective and timely public health response.
Innovation and collaboration are fundamental to any long-term strategy for addressing the ongoing pandemic and mitigating future pandemics. QIAGEN is at the forefront of these efforts, combining its knowledge and expertise with innovation. Together, we can help shape the outcome of the ongoing pandemic.
- Tillett et al. (2020) Genomic evidence for a case of reinfection with SARS-CoV-2
- Liu et al. (2020) A benchmarking study of SARS-CoV-2 whole-genome sequencing protocols using COVID-19 patient samples
- Agrawal et al. (2021) A pan-European study of SARS-CoV-2 variants in wastewater under the EU Sewage Sentinel System
- Trujillo et al. (2021) Protocol for safe, affordable, and reproducible isolation and quantitation of SARS-CoV-2 RNA from wastewater
- Farr, R. et al. (2021) Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection (plos.org)
QIAseq DIRECT SARS-CoV-2 KitAccelerate SARS-CoV-2 genomic surveillance with a 50% faster, high-throughput NGS solution. Achieve superior coverage and reduce plasticware use by 50%. Combine with the QIAseq DIRECT SARS-CoV-2 Enhancer Kit to further streamline the workflow by eliminating normalization/quantification before library amplification – and boost coverage while requiring fewer reads per sample.
QIAseq SARS-CoV-2 Primer PanelDiscover an optimized ARTIC-based solution for targeted whole genome library preparation of SARS-CoV-2 for genomic surveillance and variant detection.
NGS solutions for genomic surveillance of SARS-CoV-2For trial kits, publications, resources and more, visit our SARS-CoV-2 NGS hub.
Comprehensive SARS-CoV-2 diagnostic and research portfolioFor the latest COVID-19 solutions and resources, visit our coronavirus resource hub.